News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Mar 8, 2022

Summary Toggle aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting

SAN DIEGO , March 08, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming American Association
Mar 7, 2022

Summary Toggle aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2021 Financial Results

Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , March 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways,
Mar 3, 2022

Summary Toggle aTyr Pharma to Present at Upcoming Investor Conferences in March

SAN DIEGO , March 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla , M.D., M.S., President and Chief Executive Officer,
Feb 23, 2022

Summary Toggle aTyr Pharma to Participate in Panel at National Institutes of Health Rare Disease Day®

Panel to take place on Monday, February 28, 2022, at 2:55pm EST / 11:55am PST SAN DIEGO , Feb. 23, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today
Feb 7, 2022

Summary Toggle aTyr Pharma to Present at BIO CEO & Investor Conference

SAN DIEGO , Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla , M.D., M.S., President and Chief Executive Officer,
Jan 13, 2022

Summary Toggle aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

Efzofitimod expected to enter into a registrational trial for pulmonary sarcoidosis in 2022 SAN DIEGO , Jan. 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways,
Jan 6, 2022

Summary Toggle aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoidosis

Company expects to initiate registrational trial of ATYR1923 in pulmonary sarcoidosis in 2022 SAN DIEGO , Jan. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel
Jan 4, 2022

Summary Toggle aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

SAN DIEGO , Jan. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Jill Broadfoot , Chief Financial Officer, will present a corporate
Dec 24, 2021

Summary Toggle aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources

SAN DIEGO , Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Danielle Campbell to Vice President, Human Resources. Ms.
Dec 10, 2021

Summary Toggle aTyr Pharma to Present at Antibody Engineering & Therapeutics Conference

Novel engineering approach accelerates generation of new antibody candidates from tRNA synthetase platform. SAN DIEGO , Dec. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel